
Annual report 2025
added 02-24-2026
Globus Medical Revenue 2011-2026 | GMED
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Globus Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.94 B | 2.52 B | 1.57 B | 1.02 B | 958 M | 789 M | 785 M | 713 M | 636 M | 564 M | 545 M | 474 M | 434 M | 386 M | 331 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.94 B | 331 M | 978 M |
Quarterly Revenue Globus Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 769 M | 745 M | 598 M | 626 M | 630 M | 607 M | 384 M | 292 M | 277 M | - | 254 M | 264 M | 231 M | - | 230 M | 251 M | 227 M | 233 M | 216 M | 149 M | 191 M | 212 M | 196 M | 195 M | 183 M | 196 M | 169 M | 173 M | 174 M | 176 M | 152 M | 152 M | 156 M | 152 M | 136 M | 137 M | 139 M | 143 M | 137 M | 134 M | 132 M | 129 M | 118 M | 114 M | 114 M | 115 M | 107 M | 107 M | 105 M | 101 M | 94.8 M | 96 M | 94.7 M | 88 M | 84.3 M | 80.9 M | 78.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 769 M | 78.3 M | 219 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Butterfly Network
BFLY
|
82.1 M | $ 4.19 | 5.67 % | $ 887 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 13.73 | 1.48 % | $ 887 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 34.86 | 4.68 % | $ 5.19 K | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.51 | 5.32 % | $ 269 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 12.15 | -1.78 % | $ 1.82 B | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.1 | 0.33 % | $ 326 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
225 M | $ 31.75 | 3.15 % | $ 1.46 B | ||
|
Establishment Labs Holdings
ESTA
|
211 M | $ 59.61 | -4.85 % | $ 1.77 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.63 | 1.92 % | $ 1.14 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 82.02 | -0.58 % | $ 48 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
64 M | $ 24.49 | 5.2 % | $ 207 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.67 | 2.06 % | $ 36.5 M | ||
|
Aethlon Medical
AEMD
|
574 K | $ 2.3 | 6.48 % | $ 3.59 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.06 | 0.98 % | $ 1.25 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.43 | 5.48 % | $ 726 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 10.37 | 4.64 % | $ 1.4 B | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.35 | - | $ 21.8 M | ||
|
IRadimed Corporation
IRMD
|
83.8 M | $ 99.2 | -0.3 % | $ 1.26 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.34 | -0.22 % | $ 120 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.73 | 3.32 % | $ 139 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 16.47 | -0.3 % | $ 386 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 52.16 | -2.9 % | $ 1.53 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 63.24 | 1.69 % | $ 3.45 B | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 87.17 | 1.13 % | $ 112 B | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.39 | 2.21 % | $ 56.6 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.71 | 0.08 % | $ 29.7 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K |